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Creating a permissivemicroenvironment is a strategy employed by tumor cells to disseminate. In this issue of
Cancer Cell, Yang et al. identify the molecular signaling events that connect hepatitis infection with TGFb
activity and T regulatory cell recruitment to establish a favorable microenvironment for tumor metastasis.Metastasis is a significant contributor to
morbidity and mortality among cancer
patients. Such patients are often consid-
ered incurable, with treatments offering
either supportive care or aggressive
management without curative intent. For
over a century, cancer biologists have
intensely explored the mechanisms un-
derlying the emergence and spread of
tumor cells (Valastyan and Weinberg,
2011). Although much progress has been
made in elucidating signaling networks
of metastasis, the sheer complexity of
this dynamic and intricate process has
thwarted our ability to define effective
targets for cancer management.
An interesting form of metastases
is observed in hepatocellular carcinoma
(HCC) with a unique dissemination pattern
within the liver, a significant proportion of
which colonize inside the major branches
of the portal vein, a condition called portal
vein tumor thrombosis (PVTT). PVTT can
lead to further liver deterioration along
with ascites and esophageal bleeding,
thus presenting a major treatment chal-
lenge. A few studies have explored the
role of genomic alterations in PVTT and
have identified critical players, such
as osteopontin, in HCC metastasis (Ye
et al., 2003). Profiling of the liver microen-
vironment of metastasis patients has
shown that global shifts in inflammatory
cytokines can provide a suitable niche
to promote disease progression (Budhu
et al., 2006). A more detailed under-
standing of the complex interplay of
signals between tumors and the organs
they invade is paramount to improv-
ing cancer patient care and in develop-
ing clinical strategies to block cancer
progression.
One player at the forefront of metas-
tasis is TGFb. This multifunctional cyto-kine signals through a complex network
of transduction pathways during embry-
onic development, cell proliferation, dif-
ferentiation, angiogenesis, and wound
healing. It can function as a tumor sup-
pressor in premalignant cells by inducing
apoptosis, cell cycle arrest, and immune
surveillance while suppressing cytokines,
chemokines, and inflammation (Ikushima
and Miyazono, 2010). Its expression in
many cell types allows it to orchestrate
this vast set of processes. TGFb signals
through a canonical pathway via TGFb
receptors and its downstream Smad
mediators to recruit a network of factors
in a cell-specific and context-dependent
manner to regulate target genes. The
suppressive effects of TGFb can be cir-
cumvented by malignant cells through
inactivation of these components, such
as mutations in TGFBR2 and SMAD4.
TGFb can also signal in a noncanonical
fashion via PI3K, MAPK, and small GTP
pathways. Under these circumstances,
cancer cells can alter and seize TGFb’s
downstream tumor suppressive signaling
components to promote tumor pro-
gression. This Jekyl and Hyde nature of
TGFb can drive cancer spread via cell
autonomous or nonautonomous mecha-
nisms by impacting the host cell.
Inflammation and the tumor microenvi-
ronment play significant roles in tumor
progression and are identified as hall-
marks of cancer (Hanahan and Weinberg,
2011). A complex milieu of cells are at the
ready in the premalignant state to fend off
infection and disease, but can be usurped
by tumor cells for more insidious roles
such as metastatic initiation and progres-
sion. TGFb, an immune and inflamma-
tion regulator, is frequently present in the
microenvironment as a signal to pre-
vent premalignant progression; however,Cancer Cell 22, Semalignant cells with high TGFb may be
shielded from immune surveillance, while
defective TGFb signaling can lead to
chronic inflammation and the produc-
tion of a pro-tumorigenic environment.
Although several studies have described
a dual role for TGFb in cancer, the mech-
anisms underlying these roles and how
they can be exploited for clinical rele-
vance remains obscure. What causes
altered TGFb signaling in cancer? When
does TGFb act as a metastasis signal?
How does TGFb alter the tumor microen-
vironment? How can we use this knowl-
edge to treat cancer?
In this issue of Cancer Cell, Yang et al.
(2012) report that TGFb promotes a
metastasis-permissive microenviroment
in the portal vein of hepatitis B virus
(HBV)-positive liver cancer patients. This
switch toward a progressive phenotype
occurs through the recruitment of immune
suppressive CD4+CD25+ T regulatory
(Tregs) cells mediated by TGFb suppres-
sion of microRNA-34a (miR-34a) and the
consequent release of CCL22 activity
(Figure 1). Among 288 Chinese HCC
patients, Yang et al. (2012) found a strong
correlation between HBV status and the
presence of PVTT, concomitant with
elevated TGFb activity. In a screen of
microRNAs related to metastasis, they
found that reduced levels of miR-34a,
a tumor suppressor previously identified
in a HCC metastasis signature (Budhu
et al., 2008), was associated with HBV+
HCC and high TGFb levels. Moreover,
a quantitative assay showed that the
chemokine CCL22 is a bona fide target
of miR-34a. Using in vitro assays and
mouse models of liver or lung metastasis,
they demonstrate that TGFb signaling,
via miR-34a suppression and conse-
quent elevation of CCL22, enhancesptember 11, 2012 ª2012 Elsevier Inc. 279
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Figure 1. Cell Autonomous and Nonautonomous Activities of the
TGFb Signaling Network in Tumor and Stromal Cells
A potential therapeutic opportunity for the treatment of liver cancer metastasis
is outlined. In metastatic HCC cells, TGFb induction can be triggered by HBV
infection, which then suppressesmiR-34a, a suppressor of CCL22, resulting in
the induction and secretion of CCL22. This chemokine, in turn, recruits Tregs
to create an immune tolerant microenvironment that promotes metastatic
colonization. The balancing activities of TGFb and immune cells resemble
the principle represented by the Yin-Yang symbol. Therefore, CCL22 re-
presents a potential druggable target for metastatic HCC. The solid lines
represent a direct action, and dotted lines represent a link with an unsolved
mechanism.
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an immune suppressive mi-
croenvironment, thereby pro-
moting metastasis.
These results raise several
interesting questions and op-
portunities for further explo-
ration of TGFb signaling
and its relation to cancer
and metastasis. While the
patients studied by Yang
et al. (2012) largely consist of
HBV+ patients, several other
underlying etiologies play a
significant role in liver cancer
development. The most pro-
minent of these are hepatitis
C virus (HCV) infection,
alcoholic liver disease, and
obesity, all of which are major
global health burdens in both
developing and developed
countries. In the context of
viral infection, HBV and HCVpromote liver cancer and progression in
disparate ways. It would be of interest to
determine whether TGFb can be modu-
lated by HCV to similarly affect miR-
34a and CCL22 or different signals are
activated dependent on the risk factor
present for HCC.
Yang et al. (2012) have elegantly
demonstrated the connection between
HBV infection and the activation of Treg
recruitment to promote metastasis. In
future studies, it will be intriguing to deci-
pher how HBV affects TGFb level. Is this
due to integration of the HBV-encoded
HBx gene or some other mechanism?
The role of TGFb in HBV patients without
PVTT will be useful in determining what
drives and regulates the molecular switch
to promote metastasis. It would also be of
interest to determine how TGFb sup-
presses miR-34a. Recent studies have
shown that p53 mutation is involved in280 Cancer Cell 22, September 11, 2012 ª20switching TGFb from a tumor suppressor
to a tumor promoter (Adorno et al., 2009)
and miR-34a has been shown to be
a direct target of p53 (He et al., 2007).
The role of p53 in TGFb-mediated HBV+
HCC metastasis will be interesting to
explore since p53 mutation occurs in
certain HCC populations, while HBx
can bind and inactivate p53-dependent
processes.
TGFb targeting is quite complex,
and a clinically useful drug has not been
successfully produced. Strategies have
included reducing the ligand by siRNA,
blocking ligand-receptor interactions by
monoclonal antibodies, or inhibiting sig-
naling by small molecule inhibitors (Cal-
one and Souchelnytskyi, 2012). Yang
et al.’s study has highlighted an important
molecule in TGFb-mediated metastasis,
namely CCL22. This study therefore
opens up an avenue to explore this12 Elsevier Inc.secreted chemokine as a
target for effective treatment
of HCC metastasis. Me-
tastasis remains the major
cause of death among cancer
patients. Here, Yang et al.
(2012) have revealed an
important signaling layer of
TGFb, which sheds light on
its role in promotion of metas-
tasis and leads to a promising
therapeutic target to clinically
manage aggressive cancer.
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